IL154470A0 - Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders - Google Patents

Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders

Info

Publication number
IL154470A0
IL154470A0 IL15447001A IL15447001A IL154470A0 IL 154470 A0 IL154470 A0 IL 154470A0 IL 15447001 A IL15447001 A IL 15447001A IL 15447001 A IL15447001 A IL 15447001A IL 154470 A0 IL154470 A0 IL 154470A0
Authority
IL
Israel
Prior art keywords
acid amides
pain
prevention
derivatives
treatment
Prior art date
Application number
IL15447001A
Other languages
English (en)
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of IL154470A0 publication Critical patent/IL154470A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15447001A 2000-08-17 2001-08-17 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders IL154470A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22597700P 2000-08-17 2000-08-17
US22597300P 2000-08-17 2000-08-17
PCT/US2001/025919 WO2002013766A2 (en) 2000-08-17 2001-08-17 Valproic acid derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
IL154470A0 true IL154470A0 (en) 2003-09-17

Family

ID=26920105

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15447001A IL154470A0 (en) 2000-08-17 2001-08-17 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
IL154470A IL154470A (en) 2000-08-17 2003-02-14 Use of affluent derivatives of tungstic acid and acid 2 - tungsten acid for the preparation of a medicinal product for the treatment or prevention of pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154470A IL154470A (en) 2000-08-17 2003-02-14 Use of affluent derivatives of tungstic acid and acid 2 - tungsten acid for the preparation of a medicinal product for the treatment or prevention of pain

Country Status (21)

Country Link
US (3) US20020052418A1 (de)
EP (1) EP1311256B1 (de)
JP (1) JP2004505999A (de)
KR (1) KR100851955B1 (de)
CN (1) CN100462069C (de)
AT (1) ATE301995T1 (de)
AU (1) AU8830801A (de)
CA (1) CA2418455A1 (de)
CZ (1) CZ2004362A3 (de)
DE (1) DE60112766T2 (de)
DK (1) DK1311256T3 (de)
ES (1) ES2245377T3 (de)
HU (1) HUP0401867A2 (de)
IL (2) IL154470A0 (de)
MX (1) MXPA03001458A (de)
NO (1) NO20030724L (de)
NZ (1) NZ524687A (de)
PL (1) PL363041A1 (de)
SI (1) SI1311256T1 (de)
WO (1) WO2002013766A2 (de)
ZA (1) ZA200301427B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006012603A2 (en) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
ES2326355B1 (es) * 2008-02-25 2010-08-10 Centro Atlantico Del Medicamento, S.A. Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ATE284683T1 (de) * 1996-08-30 2005-01-15 Nps Pharma Inc Isovaleramid zur behandlung von schüttelkrämpfen, epilepsie, kopfschmerzen und spastischer lähmung
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
MXPA00012808A (es) * 1998-06-22 2002-04-24 American Biogenetic Sciences El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva.
ES2228465T3 (es) * 1999-01-19 2005-04-16 Ortho-Mcneil Pharmaceutical, Inc. Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes.

Also Published As

Publication number Publication date
KR100851955B1 (ko) 2008-08-12
ES2245377T3 (es) 2006-01-01
IL154470A (en) 2010-11-30
MXPA03001458A (es) 2004-05-04
JP2004505999A (ja) 2004-02-26
NZ524687A (en) 2005-01-28
DE60112766D1 (de) 2005-09-22
HUP0401867A2 (hu) 2004-12-28
US20020052418A1 (en) 2002-05-02
DE60112766T2 (de) 2006-03-30
NO20030724D0 (no) 2003-02-14
CN100462069C (zh) 2009-02-18
SI1311256T1 (sl) 2005-12-31
CZ2004362A3 (cs) 2005-01-12
WO2002013766A2 (en) 2002-02-21
US20090281045A1 (en) 2009-11-12
DK1311256T3 (da) 2005-11-28
EP1311256B1 (de) 2005-08-17
EP1311256A4 (de) 2004-03-24
EP1311256A2 (de) 2003-05-21
WO2002013766A3 (en) 2002-06-20
AU8830801A (en) 2002-02-25
CN1551762A (zh) 2004-12-01
US20040204495A1 (en) 2004-10-14
US8288442B2 (en) 2012-10-16
ATE301995T1 (de) 2005-09-15
NO20030724L (no) 2003-02-14
KR20030036691A (ko) 2003-05-09
ZA200301427B (en) 2004-02-23
CA2418455A1 (en) 2002-02-21
PL363041A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
AU8830801A (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
TW200510375A (en) New compounds
GB0005251D0 (en) Therapeutic compounds
ZA200107495B (en) N-cyanomethyl amides as protease inhibitors.
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
IL152337A0 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
IL143594A0 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
GEP20043286B (en) Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
MXPA05009759A (es) Combinacion de amidas de acidos fenilcarboxilicos e inhibidores del canal de ikr y su uso para tratar arritmias auriculares.
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
IL172134A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
ZA200104651B (en) Use of substituted 4-biarylbutyric 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases.